Adjuvant chemotherapy and/or radiotherapy after surgery for uterine carcinosarcoma

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Godfrey, Keith ^a   Athavale, R ^b   Deane, K H O ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UTERUS CARCINOMA; UTERUS SARCOMA;

EID: 44949100382     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006812     Document Type: Review

References (13)

1. Harlow 1986 Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. Journal of the National Cancer Institute 1986;76:339-402.
2. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
3. Major 1993 Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al.Prognostic factors in early-stage uterine sarcoma. A Gynaecologic Oncology Group study. Cancer 1993;71(Suppl 4):1702-9.
4. McCluggage 2002 McCluggage WG. Uterine carcinosarcomas (malignant mixed mullerian tumours) are metaplastic carcinomas. International Journal of Gynecological Cancer 2002;12:687-90.
5. Nielsen 1989 Nielsen SN, Podratz KC, Scheithauer BW, O'Brien PC. Clinicopathological analysis of uterine malignant mixed mullerian tumors. Gynecological Oncology 1989;34:372-8.
6. Olah 1992 Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: results of a retrospective study of 423 cases of uterine sarcoma. British Journal of Obstetrics and Gynaecology 1992;99:590-4.
7. Omura 1983 Omura GA, Blessing JA, Major F, Silverberg S. A randomised trial of adriamycin versus no adjuvant chemotherapy in stage I and stage II uterine sarcomas. Proceedings of the American Society of Clinical Oncology. 1983; Vol. C-580:149.
8. Omura 1985 Omura G, Blessing J, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al.A randomised clinical trial of adjuvant adriamycin in uterine sarcomas. a Gynecologic Oncology Group study. Journal of Clinical Oncology 1985;3:1240-5.
9. Salazar 1978 Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein ML, Dunne ME, et al.Uterine sarcomas: Analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 1978;42:1161-70.
10. Shepherd 1989 Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889-92.
11. Sutton 1997 GP Sutton, JA Blessing, LF Carson, SS Lentz, CW Whitney, HH Gallion. Adjuvant ifosfamide, mesna and cisplatin in patients with completely resected stage l or ll carcinosarcoma of the uterus: A study of the Gynecologic Oncology Group. Proceedings of the American Society Clinical Oncology. 1997; Vol. 16:362a.
12. Young 1981 Young JL, Percy CL, Asire AJ, Berg JW, Cusano MM, Gloeckler LA, et al.Cancer incidence and mortality in the United States, 1973-77. National Cancer Institute Monograph 1981;57:1-187.
13. Zelmanowicz 1998 Zelmanowicz A, Hildersheim A, Sherman ME. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumours. Gynecological Oncology 1998;69:253-7.